Safety and Immunogenicity of the Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults: Results from a Phase 2, Randomized, Controlled, Dose-Finding Trial with Long-Term Extension Follow-Up Through Month 48

<b>Background/Objectives:</b> No licensed vaccine against cytomegalovirus (CMV) is currently available, despite the significant risk of mother-to-infant transmission leading to serious neurodevelopmental impairment and the substantial morbidity caused by CMV infection in immunocompromised persons. W...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Carlos Fierro, Daniel Brune, Richard Leggett, James Peterson, Benjamin Lorenz, Renato Calabro Calheiros, Jiang Lin, Anita S. Iyer, Kai Wu, Xin Cao, Alaknanda Kondapally, Sheila Marsh, Shiva Kalidindi, Jennifer Husson, Lori Panther
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2026-05-01
Colecção:	Vaccines
Assuntos:	cytomegalovirus CMV congenital cytomegalovirus cCMV clinical trial immunogenicity
Acesso em linha:	https://www.mdpi.com/2076-393X/14/5/444
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!